Dimensional Fund Advisors LP Has $3.67 Million Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Dimensional Fund Advisors LP boosted its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 21.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 735,763 shares of the biotechnology company's stock after buying an additional 131,722 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.24% of Aldeyra Therapeutics worth $3,672,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in Aldeyra Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock valued at $5,588,000 after acquiring an additional 4,927 shares during the last quarter. Raymond James Financial Inc. bought a new position in Aldeyra Therapeutics in the fourth quarter valued at approximately $3,628,000. ADAR1 Capital Management LLC boosted its stake in Aldeyra Therapeutics by 114.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 647,960 shares of the biotechnology company's stock valued at $3,233,000 after acquiring an additional 345,748 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Aldeyra Therapeutics by 1.9% in the fourth quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company's stock valued at $1,964,000 after acquiring an additional 7,348 shares during the last quarter. Finally, Woodstock Corp lifted its stake in Aldeyra Therapeutics by 7.8% in the fourth quarter. Woodstock Corp now owns 194,919 shares of the biotechnology company's stock valued at $973,000 after buying an additional 14,113 shares during the period. Institutional investors and hedge funds own 59.71% of the company's stock.

Insider Transactions at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the firm's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the sale, the insider now directly owns 5,875,851 shares in the company, valued at $8,343,708.42. This trade represents a 36.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 9.60% of the stock is currently owned by insiders.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock remained flat at $2.16 on Friday. 809,601 shares of the stock traded hands, compared to its average volume of 778,614. Aldeyra Therapeutics, Inc has a one year low of $1.14 and a one year high of $7.20. The firm has a market cap of $129.38 million, a price-to-earnings ratio of -2.23 and a beta of 0.92. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The company has a fifty day simple moving average of $3.56 and a two-hundred day simple moving average of $4.73.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. On average, analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALDX. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, April 4th. BTIG Research cut their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday, April 7th.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.